The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis

Antikchi, Mohammad Hossein; Neámatzadeh, Hossein; Ghelmani, Yaser; Jafari-Nedooshan, Jamal; Dastgheib, Seyed Alireza; Kargar, Saeed; Noorishadkam, Mahmood; Bahrami, Reza; Jarahzadeh, Mohammad Hossein

doi:10.1007/s12029-020-00528-3

Cited by 31 publications

(36 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall pooled prevalence of COVID-19 in ESRD patients with RRT was higher than the global average prevalence (3.1% vs. 0.1%) [ 3 ]. Moreover, the overall pooled prevalence of COVID-19 in ESRD patients with RRT was higher than that of autoimmune disease patients (3.10% vs. 1.1%) [ 53 ] but was lower than that of colorectal cancer patients (3.1% vs. 45.1%) [ 54 ]. The increased prevalence in ESRD patients might relate to decreased immunity from uremia [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background The novel coronavirus (COVID-19), caused by SARS-CoV-2, showed various prevalence and case-fatality rates (CFR) among patients with different pre-existing chronic conditions. End-stage renal disease (ESRD) patients with renal replacement therapy (RRT) might have a higher prevalence and CFR due to reduced immune function from uremia and kidney tropism of SARS-CoV-2, but there was a lack of systematic study on the infection and mortality of the SARS-CoV-2 infection in ESRD patients with various RRT. Methodology/Principal findings We searched five electronic databases and performed a systematic review and meta-analysis up to June 30, 2020, to evaluate the prevalence and case fatality rate (CFR) of the COVID-19 infection among ESRD patients with RRT. The global COVID-19 data were retrieved from the international database on June 30, 2020, for estimating the prevalence and CFR of the general population as referencing points. Of 3,272 potential studies, 34 were eligible studies consisted of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions. The overall pooled prevalence in ESRD patients with RRT was 3.10% [95% confidence interval (CI) 1.25–5.72] which was higher than referencing 0.14% global average prevalence. The overall estimated CFR of COVID-19 in ESRD patients with RRT was 18.06% (95% CI 14.09–22.32) which was higher than the global average at 4.98%. Conclusions This meta-analysis suggested high COVID-19 prevalence and CFR in ESRD patients with RRT. ESRD patients with RRT should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

show abstract

Section: Discussionmentioning

confidence: 99%

Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease 2019 (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has caused significant mortality and has been declared as a global pandemic by the World Health Organization [1][2][3][4][5]. COVID-19 is a major public health concern and one of the leading cause of mortality in most countries [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis

Mirjalili

Dastgheib

Shaker

et al. 2021

J Diabetes Metab Disord

Self Cite

View full text Add to dashboard Cite

Background Currently, the number of patients with SARS-COV-2 infection has increased rapidly in Iran, but the risk and mortality of SARS-COV-2 infection in Iranian patients with diabetes mellitus (DM), chronic kidney disease (CKD), hypertension and cardiovascular diseases (CVDs) still not clear. The aim of this meta-analysis was to estimate the proportion and mortality of SARS-COV-2 in these patients. Methods A comprehensive literature search was carried out in PubMed, Web of Sciences, Cochrane Library, EMBASE, CNKI, SciELO, and other databases to identify all relevant studies published up to 10 January, 2020. The proportion and mortality in the patients were assessed by odd ratio (OR) and the corresponding 95 % confidence interval (95 % CI). Results A total of ten case-series including 11,755 cases with SARS-COV-2 infection and 942 deaths were selected. Among them, there were total of 791 DM patients with 186 deaths, 225 CKD patients with 45 deaths, 790 hypertension cases with 86 deaths, and 471 CVDs cases with 60 deaths. Pooled data revealed that the proportion of SARS-COV-2 infection in the patients with hypertension, DM, CVDs and CKD were 21.1 %, 16.3 %, 14.0 % and 5.0 %, respectively. Moreover, the SARS-COV-2 infection were associated with an increased risk of mortality in DM (OR = 0.549, CI 95 % 0.448-0.671, p ≤ 0.001) and CKD (OR = 0.552, 95 % CI 0.367-0.829, p = 0.004) patients, but not hypertension and CVDs. There was no publication bias. Conclusions Our pooled data showed that the proportion of SARS-COV-2 infection was the highest in the Iranian patients with hypertension (21.1 %) followed by DM (16.3 %), CVDs (14.0 %) and CKD (5.0 %). Moreover, DM and CKD in patients with SARS-COV-2 infection were associated with a 0.549 and 0.552-fold increase in mortality, respectively. Clinicians in Iran should be aware of these findings, to identifying patients at higher risk and inform interventions to reduce the risk of death. Moreover, well-designed, large-scale and multicenter studies are needed to improve and validate our findings.

show abstract

“…In this analysis too, the viral infection is ranked one. The common comorbid conditions such as autoimmune disease (Rank-2) [50], vascular disease (Rank-4) [71], kidney disease (Rank-5) [56, 57], neurodegenerative disease (Rank-6) [72], bone inflammation disease (Rank-7) [73], myocardial disorder (Rank-7) [74], mood disorder (Rank-7) [34], breast cancer (Rank-10) [75], liver disease (Rank-10) [58], gynaecologic cancers (Rank-11) [76], asthma (Rank-12) [77], liver cancer (Rank-13) [78], musculoskeletal abnormality (Rank-14) [63], hematologic cancer (Rank-15) [79], retinal degeneration (Rank-15) [80], sepsis / septicaemia / septic shock (Rank-15) [60, 81], diabetes (Rank-16) [82], other cardiovascular diseases (Rank-17) [71, 74], viral encephalitis (Rank-17) [83], other cognitive disorder (Rank-18) [24], immunodeficiency (Rank-19) [84], brain disease (Rank-19) [85], COPD (Rank-19) [86], gastric / colon cancer (Rank-20) [87], autism (Rank-21) [88, 89], anemia (Rank-21) [90], bone development and degenerative disease (Rank-20) [91], dyslipidaemia (Rank-22) [92, 93], and ataxia (Rank-23) [94] etc. are among the top 25 child disease categories at a cut off score of 4 ( Fig-2B ).…”

Section: Resultsmentioning

confidence: 99%

A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

Barh

Tiwari

Andrade

et al. 2020

Preprint

View full text Add to dashboard Cite

Till date the comprehensive clinical pictures, comorbid conditions, and long-term complications of COVID-19 are not known. Recently using a multi-omics-based strategy, we have predicted the drugs for COVID-19 management with ∼70% accuracy. Here, using a similar multi-omics-based bioinformatics approach and three-ways of analysis, we identified the symptoms, comorbid conditions, and short, mid and possible long-term complications of COVID-19 with ∼90% precision. In our analysis (i) we identified 27 parent, 170 child, and 403 specific conditions associated with COVID-19. (ii) Among the specific conditions, 36 are viral and 53 short-term, 62 short to mid to long-term, 194 mid to long-term, and 57 are congenital conditions. (iii) At a cut off “count of occurrence” of 4, we found ∼ 90% of the enriched conditions are associated with COVID-19. (iv) Except the dry cough and loss of taste, all other COVID-19 associated mild and severe symptoms are enriched. (v) Cardiovascular, pulmonary, metabolic, musculoskeletal, neuropsychiatric, kidney, liver, and immune system disorders are found as top comorbid conditions. (vi) Specific diseases such as myocardial infarction, hypertension, COPD, lung injury, diabetes, cirrhosis, mood disorders, dementia, macular degeneration, chronic kidney disease, lupus, arthritis etc. along with several other diseases are also enriched as top candidates. (vii) Interestingly, many cancers and congenital disorders associated with COVID-19 severity are also identified. (viii) Arthritis, dermatomyositis, glioma, diabetes, psychiatric disorder, cardiovascular diseases having bidirectional relationship with COVID-19 are also found as top ranked conditions. Based on the accuracy (∼90%) of this analysis, long presence of SARS-CoV-2 RNA in human, and our previously proposed “genetic remittance” assumption, we hypothesize that all the identified comorbid conditions including the short-long-mid and mid-long non-communicable diseases (NCDs) could also be long-term consequences in COVID-19 survivors and warrants long-term observational studies.

show abstract

The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis

Cited by 31 publications

References 34 publications

Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis

A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

Contact Info

Product

Resources

About